Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)
Close on Nov 17, 2026Market cap $508.30KP/E –Yield –
Lakewood-Amedex Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.51M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$886.75K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$637.38K | – |
| Q1 FY2025 | Mar 31, 2025 | -$542.61K | – |
See a number that looks wrong?